Pulse Biosciences, Inc. (PLSE)
Stock Price:
$12.16 USD
0.03 (0.25%)
Updated Oct 29, 2020 9:30 AM EDT - Market open
Key Info
| Market Cap |
306.58M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-48.74M |
| Shares Out |
25.21M |
| EPS (ttm) |
-2.32 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 29, 2020 |
| Last Price |
$12.16 |
| Previous Close |
$12.13 |
| Change ($) |
0.03 |
| Change (%) |
0.25% |
| Day's Open |
- |
| Day's Range |
12.07 - 12.16 |
| Day's Volume |
1,143 |
| 52-Week Range |
5.11 - 17.77 |
More Stats
| Market Cap |
306.58M |
| Enterprise Value |
279.98M |
| Earnings Date (est) |
Nov 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
25.21M |
| Float |
12.92M |
| EPS (basic) |
-2.33 |
| EPS (diluted) |
-2.32 |
| FCF / Share |
-1.64 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.36M |
| Short Ratio |
19.28 |
| Short % of Float |
18.25% |
| Beta |
1.77 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
7.37 |
| Revenue |
n/a |
| Operating Income |
-49.20M |
| Net Income |
-48.74M |
| Free Cash Flow |
-35.32M |
| Net Cash |
26.60M |
| Net Cash / Share |
1.06 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-53.29% |
| ROE |
-105.74% |
| ROIC |
-192.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
16.0
Current: $12.16
High
16.0
Target: 16.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -47.95 | -37.96 | -25.81 | -9.59 | -4.47 |
| Net Income | -46.97 | -37.55 | -25.57 | -9.52 | -2.81 |
| Shares Outstanding | 20.75 | 17.08 | 14.75 | 11.01 | 7.57 |
| Earnings Per Share | -2.26 | -2.20 | -1.73 | -0.86 | -0.37 |
| Operating Cash Flow | -34.19 | -23.90 | -11.09 | -8.05 | -3.32 |
| Capital Expenditures | -0.61 | -0.28 | -2.55 | -0.06 | -0.09 |
| Free Cash Flow | -34.79 | -24.17 | -13.64 | -8.12 | -3.40 |
| Cash & Equivalents | 25.40 | 59.58 | 38.07 | 16.40 | 3.61 |
| Total Debt | 6.72 | - | - | - | - |
| Net Cash / Debt | 18.68 | 59.58 | 38.07 | 16.40 | 3.61 |
| Assets | 41.92 | 70.64 | 49.82 | 26.31 | 14.33 |
| Liabilities | 11.18 | 4.31 | 3.83 | 1.02 | 0.66 |
| Book Value | 30.74 | 66.33 | 46.00 | 25.30 | 13.67 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Pulse Biosciences, Inc. |
| Country |
United States |
| Employees |
82 |
| CEO |
Darrin R. Uecker |
Stock Information
| Ticker Symbol |
PLSE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Instruments & Supplies |
| Unique Identifier |
NASDAQ: PLSE |
| IPO Date |
May 18, 2016 |
Description
Pulse Biosciences operates as a novel bioelectric medicine company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.